SRC and neoplasm: Incubation of CAFs with Desatinib, a small molecule inhibitor of multiple target kinases, including BCR-ABL and members of the SRC family, partially reverses the CAF phenotype and gene expression profile to that of NFs, and reduces the effects of CAF CM that promote tumor cell proliferation [516].